Mekinist (Trametinib)

Trametinib blocks the activity of MEK1 and MEK2 kinases, which are central components of the MAPK/ERK signaling cascade. By inhibiting MEK, the drug prevents ERK activation and downstream gene transcription that drives tumor cell proliferation and survival, especially in cancers driven by upstream BRAF or KRAS mutations.

The exact dose of Mekinist is set by the prescribing oncologist based on the specific indication, patient weight, renal and hepatic function, and any concomitant therapies. Dosing recommendations are provided in the product labeling, and adjustments may be made according to clinical response and tolerability.

Safety data for trametinib in pregnancy and lactation are limited. The drug should be avoided unless the potential benefit justifies the potential risk to the fetus. Women of childbearing potential should use effective contraception during treatment and for a defined period after the last dose. Breastfeeding is not recommended while on therapy.

To request Mekinist, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Mekinist (trametinib) is a selective MEK1/2 inhibitor with a well‑characterised safety profile. Compared with other MEK inhibitors, it offers once‑daily oral dosing and has demonstrated efficacy in BRAF‑mutated melanoma and KRAS‑mutated lung cancer when combined with appropriate partners. Choice of MEK inhibitor often depends on the approved indication, combination regimen, and individual patient tolerability.

Mekinist tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the product out of reach of children and avoid exposure to excessive heat or humidity. No refrigeration is required.

Mekinist is taken orally, usually once daily, with or without food, as directed by the treating physician. The tablets should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed and not alter the dose without medical advice.

Serious adverse events linked to trametinib include cardiac dysfunction such as reduced left ventricular ejection fraction, severe skin reactions like Stevens‑Johnson syndrome, interstitial lung disease or pneumonitis, significant liver injury, and hemorrhagic events. Patients should be monitored regularly for these conditions, and therapy should be discontinued if severe toxicity occurs.

Mekinist is contraindicated in patients with known hypersensitivity to trametinib or any excipients in the tablet. It should be avoided in individuals receiving strong CYP3A4 inducers that would markedly lower drug exposure, and in patients with uncontrolled cardiac disease or severe hepatic impairment unless specifically advised by a specialist.